-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:Match Group公佈的第一季業績顯示,營收為8.64億美元(年成長4%),超越市場普遍預期的8.54億美元;調整後EBITDA為3.43億美元(年成長25%),遠超過先前3.17億美元的預期,反映出公司營運紀律的改善。本季最令人鼓舞的進展是Tinder的復甦勢頭,各項用戶參與度指標均有所改善,包括Sparks覆蓋率年增6%,每月活躍用戶數降幅收窄至7%,為31個月以來的最低水準。管理階層給出的第二季營收預期為8.5億至8.6億美元,其中已考慮了Tinder用戶體驗測試和Azar持續面臨的壓力等預期不利因素。 Hinge持續保持強勁成長勢頭,營收成長28%至1.94億美元,正朝著10億美元的目標穩步邁進。我們認為,Tinder 用戶參與度的提升驗證了其轉型策略,儘管獲利模式的轉變仍較為緩慢,營收年增僅 2%。公司推行的效率提升措施將協助其重振旗鼓,目標是在 2027 年實現 Tinder 的復甦。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.